Table 2.
Treatment regimens of n = 142 patients with advanced pancreatic cancer.
| Treatment Regimens | Patients Receiving Chemotherapy (n = 142) | |
|---|---|---|
| First line treatment, n (%) | 142 (100) | |
| Duration of therapy (days), median (Q1;Q3) | 90.0 (53.0;153.0) | |
| Discontinued, n (%) | 140 (98.6) | |
| Gemcitabine, n (%) | 43 (30.3) | |
| Gemcitabine/nab-Paclitaxel, n (%) | 48 (33.8) | |
| FOLFIRINOX, n (%) | 51 (35.9) | |
| Second line treatment, n (%) | 70 (49.3) | |
| Duration of therapy (days), median (Q1;Q3) | 61.0 (31.0;96.0) | |
| Discontinued, n (%) | 69 (48.6) | |
| Gemcitabine, n (%) | 33 (23.2) | |
| Gemcitabine/nab-Paclitaxel, n (%) | 27 (19.0) | |
| FOLFIRINOX, n (%) | 10 (7.0) | |
| Third line treatment, n (%) | 17 (12.0) | |
| Duration of therapy (days), median (Q1;Q3) | 89.5 (45.5;106.0) | |
| Discontinued, n (%) | 17 (12.0) | |
Data are shown as numbers (percentage) or median (Q1;Q3). FOLFIRINOX, folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin; n, number.